{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:06:23Z","timestamp":1777010783181,"version":"3.51.4"},"reference-count":18,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Non\u2013small cell lung cancer (NSCLC) is a heterogeneous disease with diverse molecular alterations. Two of the most common genetic abnormalities found in advanced NSCLC are mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the ROS proto-oncogene 1 (ROS-1). Although these two alterations are typically mutually exclusive, there have been reports of their co-occurrence in a small subset of NSCLC patients. The discovery of this comutation has recently become apparent due to the increased use of more sensitive whole genome sequencing. We share our experience with two cases of coexisting EGFR and ROS-1 alterations. The first case is a 60-year-old man diagnosed with advanced adenocarcinoma of the lung with metastasis to bone and left adrenal gland. The second case is a 49-year-old woman diagnosed with stage IV lung adenocarcinoma with metastasis to the contralateral lung and diffuse abdominal lymphadenopathy. The first case was treated with osimertinib, and currently has had a stable disease on this medication for more than 3 years. The second case had a short interval of stable disease on osimertinib; then she developed progressive disease with poor response to anti\u2013ROS-1 therapy. We believe patients with advanced NSCLC may have a higher incidence of coalterations, especially in the areas of the world with higher EGFR mutations and in the era of higher usage of whole genome sequencing. The presence of comutations will allow for a good long-term response to anti-EGFR therapy. This highlights the importance of the use of next-generation sequencing whenever possible and considers variant allele frequency as a factor in directing the therapy. There are many other unanswered questions, such as the best treatment sequencing or even the combined targeted therapy approach. This case series may add some information to the current literature.<\/jats:p>","DOI":"10.36401\/jipo-23-48","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:02:17Z","timestamp":1717714937000},"page":"300-303","source":"Crossref","is-referenced-by-count":2,"title":["Case Series: EGFR and ROS-1 Co-Occurrence in Advanced Non\u2013Small Cell Lung Cancer"],"prefix":"10.36401","volume":"7","author":[{"given":"Turki","family":"Alfayea","sequence":"first","affiliation":[{"name":"1 Department of Oncology, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia"},{"name":"2 King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"3 King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa A.","family":"Salim","sequence":"additional","affiliation":[{"name":"4 Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-6050","authenticated-orcid":true,"given":"Mohammad","family":"Alkaiyat","sequence":"additional","affiliation":[{"name":"1 Department of Oncology, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia"},{"name":"2 King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"3 King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Al-Rehaily","sequence":"additional","affiliation":[{"name":"5 Department of Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2024103123504160000_i2590-017X-7-4-300-b01","article-title":"Cancer incidence report 2020 - Saudi Arabia","year":"2020"},{"key":"2024103123504160000_i2590-017X-7-4-300-b02","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3892\/mco.2015.644","article-title":"Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region","volume":"3","author":"Jazieh","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b03","doi-asserted-by":"crossref","first-page":"610923","DOI":"10.3389\/fonc.2020.610923","article-title":"Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer: a review","volume":"10","author":"Guo","year":"2020","journal-title":"Front Oncol"},{"issue":"15_suppl","key":"2024103123504160000_i2590-017X-7-4-300-b04","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e19003","article-title":"ROS1 rearrangement coexists with EGFR mutation in non-small-cell lung cancer","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b05","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.2147\/OTT.S133349","article-title":"ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma","volume":"10","author":"Mao","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2024103123504160000_i2590-017X-7-4-300-b06","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2016.08.137","article-title":"High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer","volume":"12","author":"Wiesweg","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b07","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b08","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1186\/s12885-018-4774-y","article-title":"EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"18","author":"Benbrahim","year":"2018","journal-title":"BMC Cancer"},{"key":"2024103123504160000_i2590-017X-7-4-300-b09","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2024103123504160000_i2590-017X-7-4-300-b10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2024103123504160000_i2590-017X-7-4-300-b11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"2024103123504160000_i2590-017X-7-4-300-b12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent advances in targeting ROS1 in lung cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024103123504160000_i2590-017X-7-4-300-b16","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.2147\/OTT.S136297","article-title":"Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant","volume":"10","author":"Zhao","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2024103123504160000_i2590-017X-7-4-300-b17","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.cllc.2017.08.005","article-title":"ROS1-rearranged non-small cell lung cancers with concomitant oncogenic driver alterations: about some rare therapeutic dilemmas","volume":"19","author":"Lambros","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024103123504160000_i2590-017X-7-4-300-b18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cllc.2015.11.004","article-title":"Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and response to therapy","volume":"17","author":"Ulivi","year":"2016","journal-title":"Clin Lung Cancer"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/4\/300\/3446594\/i2590-017x-7-4-300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/4\/300\/3446594\/i2590-017x-7-4-300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:23Z","timestamp":1765475303000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/7\/4\/article-p300.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-48","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}